ARFGEF2 sirna

ARFGEF2 siRNA (Rat)

Cat. Num. AAA8237111

• Gene Names: Arfgef2; Big2
• Reactivity: Rat
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: ARFGEF2; ARFGEF2 siRNA (Rat); ARFGEP2; BIG2; Brefeldin A-inhibited guanine nucleotide-exchange protein 2; Brefeldin A-inhibited GEP 2; ADP-ribosylation factor guanine nucleotide-exchange factor 2; ARFGEF2 sirna

• Host: Synthetic
• Reactivity: Rat
• Specificity: ARFGEF2 siRNA (Rat) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 1,791

• Applicable Applications for ARFGEF2 sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of rat ARFGEF2 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for ARFGEF2 sirna

siRNA to inhibit ARFGEF2 expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 31342051
• NCBI GeneID: 296380
• NCBI Accession #: NP_851597.2
• NCBI GenBank Nucleotide #: NM_181083.2
• UniProt Accession #: Q7TSU1
• Molecular Weight: 201,974 Da
• NCBI Official Full Name: brefeldin A-inhibited guanine nucleotide-exchange protein 2
• NCBI Official Synonym Full Names: ADP-ribosylation factor guanine nucleotide-exchange factor 2 (brefeldin A-inhibited)
• NCBI Official Symbol: Arfgef2
• NCBI Official Synonym Symbols: Big2
• NCBI Protein Information: brefeldin A-inhibited guanine nucleotide-exchange protein 2
• UniProt Protein Name: Brefeldin A-inhibited guanine nucleotide-exchange protein 2
• UniProt Gene Name: Arfgef2
• UniProt Synonym Gene Names: Arfgep2; Big2; Brefeldin A-inhibited GEP 2
• UniProt Entry Name: BIG2_RAT

Uniprot Description

ARFGEF2: Promotes guanine-nucleotide exchange on ARF1 and ARF3 and to a lower extend on ARF5 and ARF6. Promotes the activation of ARF1/ARF5/ARF6 through replacement of GDP with GTP. Involved in the regulation of Golgi vesicular transport. Required for the integrity of the endosomal compartment. Involved in trafficking from the trans-Golgi network (TGN) to endosomes and is required for membrane association of the AP-1 complex and GGA1. Seems to be involved in recycling of the transferrin receptor from recycling endosomes to the plasma membrane. Probably is involved in the exit of GABA(A) receptors from the endoplasmic reticulum. Involved in constitutive release of tumor necrosis factor receptor 1 via exosome-like vesicles; the function seems to involve PKA and specifically PRKAR2B. Proposed to act as A kinase-anchoring protein (AKAP) and may mediate crosstalk between Arf and PKA pathways. Defects in ARFGEF2 are the cause of autosomal recessive periventricular nodular heterotopia type 2 (PVNH2); also known as periventricular heterotopia with microcephaly autosomal recessive. PVNH is a developmental disorder characterized by the presence of periventricular nodules of cerebral gray matter, resulting from a failure of neurons to migrate normally from the lateral ventricular proliferative zone, where they are formed, to the cerebral cortex. PVNH2 is an autosomal recessive form characterized by microcephaly (small brain), severe developmental delay and recurrent infections. No anomalies extrinsic to the central nervous system, such as dysmorphic features or grossly abnormal endocrine or other conditions, are associated with PVNH2.

Protein type: GEFs, ARF; GEFs

Cellular Component: asymmetric synapse; Golgi membrane; recycling endosome; membrane; perinuclear region of cytoplasm; cytoplasmic membrane-bound vesicle; cytoplasm; dendritic spine; microtubule organizing center; cytoplasmic vesicle; trans-Golgi network; cell junction; cytosol

Molecular Function: protein binding; myosin binding; guanyl-nucleotide exchange factor activity; GABA receptor binding; ARF guanyl-nucleotide exchange factor activity

Biological Process: receptor recycling; Golgi to plasma membrane transport; protein transport; exocytosis; endosome organization and biogenesis; endomembrane organization; regulation of ARF protein signal transduction; positive regulation of tumor necrosis factor production; positive regulation of GTPase activity